左旋咪唑在儿童微小病变型肾病中的抗复发作用  被引量:2

Anti-relapse of Levamisole in children with minimal change nephropathy

在线阅读下载全文

作  者:赵德安[1] 杨达胜[1] 韩子明[1] 陈新德[1] 

机构地区:[1]新乡医学院第一附属医院儿内科,河南卫辉453100

出  处:《新乡医学院学报》2006年第3期225-226,共2页Journal of Xinxiang Medical University

基  金:河南省自然科学基金资助项目(No.964024900)

摘  要:目的探讨左旋咪唑在初治激素敏感微小病变型肾病中的抗复发作用。方法选取临床住院初治微小病变型肾病患儿32例作为研究对象,在激素常规治疗的基础上加用左旋咪唑(左旋咪唑组),以激素常规治疗的13例肾病综合征患儿为对照。观察两组患儿T细胞免疫、复发率以及并发症的发生情况。结果左旋咪唑组平均每个患儿每月复发率为0.16次,对照组为0.36次,两组比较有显著差异(P<0.05)。左旋咪唑组治疗后CD3、CD4和CD4+/CD8+比率升高(P<0.05),与对照组比较有显著差异(P<0.05)。与对照组比较,左旋咪唑组感染率明显降低(P<0.05),病程中仅出现2例可逆短暂性的白细胞减少。结论左旋咪唑是治疗初治激素敏感微小病变型肾病的一种有效、安全、经济的抗复发药物。Objective To study anti- relapse of Levamisole in children with minimal change nephropathy. Methods Thirty two inpatients with minimal change nephropathy performed with preliminary treatment by routine hormone were administered with Levarnisole plus hormone. Thirteen children with nephrotic syndrome performed with treatment of routine hormone were classified as control group. T cell immunlty, relapse rate and occurrence of complications in two groups were evaluated before and after treatment. Results Relapse rate was 0. 16 times in per child monthly in group performed with Levarnisole, and that in control group was 0.36 times. There was significant difference between two groups (P〈0.05). Increment of CD3, CD4 and ratio of CD4^+ versus CD8^+ (P〈0.05), which was significant difference compared to the control group (P 〈 0.05). Compared to the control group, infection rate was decreased obviously in group of Levamisole (P 〈 0.05) and 2 cases of reversible transient hypolekocytosi occurred. Conclusion Levamisole is an efficacious , safe and economical antirelapse drug for the treatment of patients with minimal change nephropathy performed with preliminary treatment by routine hormone.

关 键 词:肾病综合征 微小病变 左旋咪唑 复发 细胞免疫 儿童 

分 类 号:R692[医药卫生—泌尿科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象